StreetInsider.com News Articles

Aptevo reports 93% clinical benefit rate in TP53-mutated AML trial

Thu, 03 Sep 2026 08:06:58 -0400

Aptevo Therapeutics Inc. (Nasdaq: APVO) reported a 93% clinical benefit rate in a small group of frontline acute myeloid leukemia (AML) patients with TP53 mutations treated with its mipletamig drug candidate in combination with venetoclax and azacitidine, according to a company statement.

Of 14 evaluable patients treated with the triplet combination, 13 experienced clinical benefit. Eleven patients, or 79%, achieved complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), including nine complete remissions.

The company compared the 79% CR/CRi rate to a published 41% composite remission rate for venetoclax plus azacitidine alone in treatment-naïve patients with poor-risk cytogenetics and TP53-mutated

Aptevo reports 93% clinical benefit rate in TP53-mutated AML trial

Thu, 03 Sep 2026 08:06:58 -0400

The company compared the 79% CR/CRi rate to a published 41% composite remission rate for venetoclax plus azacitidine alone in treatment-naïve patients with poor-risk cytogenetics and TP53-mutated

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Thu, 03 Sep 2026 08:05:00 -0400

Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success

SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced a 93% clinical benefit rate with its mipletamig triplet in evaluable frontline acute myeloid leukemia (AML) patients with TP53 mutations, one of the most difficult-to-treat forms of the disease and a patient population that has historically responded poorly to treatment.

"TP53-mutated AML remains one of the most challenging AML subpopulations to treat," said Dirk

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML

Thu, 03 Sep 2026 08:05:00 -0400

Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success

"TP53-mutated AML remains one of the most challenging AML subpopulations to treat," said Dirk

Form D Aptevo Therapeutics Inc.

Wed, 26 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260826/26981557.html

Form D Aptevo Therapeutics Inc.

Wed, 26 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260826/26981557.html

Form PRE 14A Aptevo Therapeutics Inc. For: Aug 21

Fri, 21 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260821/26961603.html

Form PRE 14A Aptevo Therapeutics Inc. For: Aug 21

Fri, 21 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260821/26961603.html

Aptevo Therapeutics files prospectus for resale of 6.4M shares

Fri, 21 Aug 2026 16:13:07 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) filed a prospectus related to the potential resale of up to 6,444,858 shares of common stock, par value $0.001 per share, by certain selling stockholders.

The shares are issuable upon the exercise of three types of warrants: pre-funded common stock purchase warrants covering up to 861,708 shares, common stock purchase warrants covering up to 4,308,540 shares, and inducement warrants covering up to 1,274,610 shares.

The pre-funded warrants and common warrants were issued through a private placement under a Securities Purchase Agreement dated August 12, 2026. The inducement warrants were issued pursuant to Warrant Inducement and Reload Letters,

Aptevo Therapeutics files prospectus for resale of 6.4M shares

Fri, 21 Aug 2026 16:13:07 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO) filed a prospectus related to the potential resale of up to 6,444,858 shares of common stock, par value $0.001 per share, by certain selling stockholders.

Form S-1 Aptevo Therapeutics Inc.

Fri, 21 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260821/26961484.html

Form S-1 Aptevo Therapeutics Inc.

Fri, 21 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260821/26961484.html

Form 8-K Aptevo Therapeutics Inc. For: Aug 21

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961376.html

Form 8-K Aptevo Therapeutics Inc. For: Aug 21

Fri, 21 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260821/26961376.html

Form SCHEDULE 13G/A Aptevo Therapeutics Inc. Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26929119.html

Form SCHEDULE 13G/A Aptevo Therapeutics Inc. Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26929119.html

Form 10-Q Aptevo Therapeutics Inc. For: Jun 30

Fri, 14 Aug 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26924996.html

Form 10-Q Aptevo Therapeutics Inc. For: Jun 30

Fri, 14 Aug 2026 08:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26924996.html

Form 8-K Aptevo Therapeutics Inc. For: Aug 14

Fri, 14 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26924966.html

Form 8-K Aptevo Therapeutics Inc. For: Aug 14

Fri, 14 Aug 2026 08:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26924966.html

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Fri, 14 Aug 2026 08:05:00 -0400

Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2

Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline

Non-Dilutive Grant Funding Advances APVO451 and Validates Trispecific Solid Tumor Strategy

Strategic Niowave Collaboration Opens a New Radiopharmaceutical Therapeutic Development Opportunity

SEATTLE, WA / ACCESS Newswire / August 14, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ended June 30, 2026 and provided a business update highlighting strong clinical progress

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Fri, 14 Aug 2026 08:05:00 -0400

Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2

Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline

Non-Dilutive Grant Funding Advances APVO451 and Validates Trispecific Solid Tumor Strategy

Strategic Niowave Collaboration Opens a New Radiopharmaceutical Therapeutic Development Opportunity

Form 8-K Aptevo Therapeutics Inc. For: Aug 12

Thu, 13 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260813/26922051.html

Form 8-K Aptevo Therapeutics Inc. For: Aug 12

Thu, 13 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260813/26922051.html

Aptevo Therapeutics raises $4.5M through warrant exercise and PIPE

Thu, 13 Aug 2026 16:06:28 -0400

Aptevo Therapeutics Inc. (NASDAQ: APVO), a clinical-stage biotechnology company, closed a warrant inducement transaction and a private placement on August 13, 2026, raising approximately $4.5 million in gross proceeds before placement agent fees and expenses.

In the warrant inducement transaction, certain holders of existing common warrants exercised their warrants in full for cash to purchase an aggregate of 254,922 shares of common stock at a reduced exercise price of $4.03 per share. In exchange, the company issued new unregistered inducement warrants to purchase up to 1,274,610 shares of common stock at the same $4.03 exercise price. These inducement warrants will become